Diskussionsleiter: S. Greulich (Tübingen), S. Mrotzek (Essen)
| (P1225) | High prevalence of cancer in patients with peripartum cardiomyopathy and potential pathophysiological connections | |
| T. Pfeffer, S. Schlothauer, S. Pietzsch, M. Schaufelberger, K. Sliwa-Hähnle, C. Falk, S. Haidari, M. Ricke-Hoch, E. Stelling, D. Berliner, V. Abou Moulig, T. König, M. Kasten, J. Bauersachs, D. Hilfiker-Kleiner (Hannover; Göteborg, SE; Kapstadt, ZA) | ||
| (P1226) | Reversibility of cancer cachexia induced cardiac alterations and functional impairment | |
| S. Pietzsch, K. Wohlan, S. Erschow, J. T. Thackeray, M. Scherr, D. Hilfiker-Kleiner (Hannover) | ||
| (P1227) | PD1-blocking immune checkpoint inhibitor therapy for malignant melanoma induces left ventricular dysfunction | |
| L. Michel, U. Hendgen-Cotta, D. Schadendorf, T. Rassaf, M. Totzeck (Essen) | ||
| (P1228) | Changes of ion channel expression and functions induced by Esophageal Cancer Related Gene-4 knock-down in human-induced stem cell-derived cardiomyocytes | |
| Q. Xu, H. Lan, I. El-Battrawy, Z. Zhao, X. Li, M. Huang, R. Zhong, Z. Liao, S. Lang, W.-H. Zimmermann, L. Cyganek, T. Wieland, X. Zeng, X. Dang, M. Borggrefe, X. Zhou, I. Akin (Mannheim, Göttingen; Luzhou, CN) | ||
| (P1229) | Regulation of the cardiac NLRP3 inflammasome in type 2 diabetes progression | |
| A. Fender, S. Stolte, S. Kleeschulte, D. Dobrev (Essen, Düsseldorf) | ||
| (P1230) | Plasminogen activator inhibitor type-1 (PAI-1) expression relates to the presence of myocardial inflammation in patients with nonischemic cardiomyopathy | |
| F. Escher, M. Agirbasli, D. Lassner, G. Aleshcheva, H.-P. Schultheiss (Berlin; Istanbul, TR) | ||
| (P1232) | Immediate versus delayed detection of Takotsubo syndrome after epileptic seizures | |
| C. Stöllberger, M. Sauerberg, J. Finsterer (Wien, AT) |
